The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Oncology Institute Inc (NASDAQ: TOI) closed at $3.71 in the last session, up 4.80% from day before closing price of $3.54. In other words, the price has increased by $4.80 from its previous closing price. On the day, 1.83 million shares were traded. TOI stock price reached its highest trading level at $3.75 during the session, while it also had its lowest trading level at $3.5.
Ratios:
We take a closer look at TOI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.59 and its Current Ratio is at 1.79. In the meantime, Its Debt-to-Equity ratio is 20.18 whereas as Long-Term Debt/Eq ratio is at 18.83.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Noble Capital Markets on July 23, 2025, initiated with a Outperform rating and assigned the stock a target price of $8.
On July 16, 2025, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $6.
On May 15, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $7.BTIG Research initiated its Buy rating on May 15, 2025, with a $7 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 05 ’25 when M33 Growth I L.P. sold 673,676 shares for $3.05 per share. The transaction valued at 2,054,712 led to the insider holds 13,950,557 shares of the business.
M33 Growth I L.P. sold 76,324 shares of TOI for $232,788 on Jun 05 ’25. The Director now owns 1,272,724 shares after completing the transaction at $3.05 per share. On Jun 03 ’25, another insider, Hively Brad, who serves as the Director of the company, sold 1,976,137 shares for $2.87 each. As a result, the insider received 5,672,106 and left with 603,501 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TOI now has a Market Capitalization of 340999808 and an Enterprise Value of 393716544. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.85 while its Price-to-Book (P/B) ratio in mrq is 65.09. Its current Enterprise Value per Revenue stands at 0.977 whereas that against EBITDA is -8.658.
Stock Price History:
The Beta on a monthly basis for TOI is 0.08, which has changed by 5.9868174 over the last 52 weeks, in comparison to a change of 0.17774606 over the same period for the S&P500. Over the past 52 weeks, TOI has reached a high of $3.78, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is 32.70%, while the 200-Day Moving Average is calculated to be 179.73%.
Shares Statistics:
According to the various share statistics, TOI traded on average about 2.04M shares per day over the past 3-months and 2904310 shares per day over the past 10 days. A total of 88.93M shares are outstanding, with a floating share count of 45.65M. Insiders hold about 50.33% of the company’s shares, while institutions hold 14.64% stake in the company. Shares short for TOI as of 1751241600 were 5769768 with a Short Ratio of 2.83, compared to 1748563200 on 1559896. Therefore, it implies a Short% of Shares Outstanding of 5769768 and a Short% of Float of 7.6899999999999995.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
According to 3 analysts, the current quarter’s revenue is expected to be $113.17M. It ranges from a high estimate of $116.6M to a low estimate of $110.35M. As of the current estimate, Oncology Institute Inc’s year-ago sales were $98.58MFor the next quarter, 3 analysts are estimating revenue of $121.25M. There is a high estimate of $122.6M for the next quarter, whereas the lowest estimate is $119.49M.
Based on 3 analysts’ estimates, the company’s revenue will be $556.23M in the next fiscal year. The high estimate is $582.35M and the low estimate is $536.33M.
